Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Leena E. Youssefian"'
Autor:
Xin-Yan Pei, Yun Dai, Jessica Felthousen, Shuang Chen, Yukie Takabatake, Liang Zhou, Leena E Youssefian, Michael W Sanderson, Wesley W Bodie, Lora B Kramer, Robert Z Orlowski, Steven Grant
Publikováno v:
PLoS ONE, Vol 9, Iss 3, p e89064 (2014)
The anti-apoptotic protein Mcl-1 plays a major role in multiple myeloma (MM) cell survival as well as bortezomib- and microenvironmental forms of drug resistance in this disease. Consequently, there is a critical need for strategies capable of target
Externí odkaz:
https://doaj.org/article/3c9abcdb83b1404890faef5d609aa231
Autor:
Paul Dent, Yukie Takabatake, Lora Kramer, Jorge A. Almenara, Xin-Yan Pei, Leena E. Youssefian, Steven Grant, Yun Dai, Wesley W. Bodie, Jessica Felthousen, Shuang Chen
Publikováno v:
Blood. 118:5189-5200
Effects of Chk1 and MEK1/2 inhibition were investigated in cytokinetically quiescent multiple myeloma (MM) and primary CD138+ cells. Coexposure to the Chk1 and MEK1/2 inhibitors AZD7762 and selumetinib (AZD6244) robustly induced apoptosis in various
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e90a7979ef73d3a5ab2954299a97e73
https://doi.org/10.1182/blood-2011-02-339432
https://doi.org/10.1182/blood-2011-02-339432
Autor:
Liang Zhou, Wesley W. Bodie, Jessica Felthousen, Robert Z. Orlowski, Shuang Chen, Xin Yan Pei, Lora Kramer, Michael W. Sanderson, Leena E. Youssefian, Yun Dai, Steven Grant, Yukie Takabatake
Publikováno v:
PLoS ONE
PLoS ONE, Vol 9, Iss 3, p e89064 (2014)
PLoS ONE, Vol 9, Iss 3, p e89064 (2014)
The anti-apoptotic protein Mcl-1 plays a major role in multiple myeloma (MM) cell survival as well as bortezomib- and microenvironmental forms of drug resistance in this disease. Consequently, there is a critical need for strategies capable of target
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aecf1022ca785e509cda664737c0b904
https://pubmed.ncbi.nlm.nih.gov/24594907
https://pubmed.ncbi.nlm.nih.gov/24594907
Autor:
Yun Dai, Michael W. Sanderson, Lora Kramer, Jessica Felthousen, Steven Grant, Xin-Yan Pei, Leena E. Youssefian
Publikováno v:
Blood. 124:4763-4763
Introduction: Multiple myeloma (MM) is characterized by deregulation of members of the Bcl-2 family of apoptotic regulatory proteins. This has led to the development of BH3-mimetics such as ABT-737 which inhibits Bcl-2/xL but not Mcl-1. Previously, w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::77a2f4067049307960230cf96e7069d5
https://doi.org/10.1182/blood.v124.21.4763.4763
https://doi.org/10.1182/blood.v124.21.4763.4763
Autor:
Andrew Poklepovic, Leena E. Youssefian, Nancy A. Crosby, Christine A. Birdsell, Marc S. Ernstoff, John D. Roberts, Mary Winning, Viswanathan Ramakrishnan
Publikováno v:
Investigational New Drugs. 31:1095-1095
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ac283be73160e94e561018c3cf65ccef
https://doi.org/10.1007/s10637-013-9997-9
https://doi.org/10.1007/s10637-013-9997-9
Autor:
Xin-Yan Pei, Yun Dai, Jessica Felthousen, Shuang Chen, Yukie Takabatake, Leena E. Youssefian, Wesley W. Bodie, Lora B. Kramer, Robert Z. Orlowski, Steven Grant
Publikováno v:
Cancer Research. 73:3390-3390
Mcl-1 is a critical survival factor for human multiple myeloma (MM) cells, and also confers resistance to various anti-MM agents, including bortezomib (btz). We have previously reported that exposure of MM cells to Chk1 inhibitors elicits activation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c53289cf7e353ec6c59269af4ff0459
https://doi.org/10.1158/1538-7445.am2013-3390
https://doi.org/10.1158/1538-7445.am2013-3390
Autor:
Yukie Takabatake, Lora Kramer, Yun Dai, Wesley W. Bodie, Xin-Yan Pei, Shuang Chen, Paul Dent, Steven Grant, George Almenara, Leena E. Youssefian
Publikováno v:
Cancer Research. 71:5367-5367
One potential barrier to successful multiple myeloma (MM) treatment stems from the observation that it generally represents a low growth fraction disease with cells resting in a quiescent, non-proliferative state (i.e., < 5% of cells actively cycling
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b345e48d819a01fcc287ea034088ac8a
https://doi.org/10.1158/1538-7445.am2011-5367
https://doi.org/10.1158/1538-7445.am2011-5367